New cocktail of drugs shows promise for stomach cancer patients
NCT ID NCT05927857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced stomach cancer that has spread and who have already tried one type of treatment. It tests a combination of three drugs (ramucirumab, nal-IRI, and trifluridine/tipiracil) to see if they can shrink tumors and help patients live longer. The study has two phases: first to find the best dose, then to measure how well the treatment works. About 45 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan/Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI writing coach help chemo patients feel less anxious?
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Breast reconstruction after mastectomy: which approach leads to happier patients?
- Virtual reality tested as a calming tool during chemo
- New hope for elderly lymphoma patients: a gentler treatment that preserves independence
- Acupuncture with a jolt: could needles shield nerves from chemo?